Drug Interaction Report

GENERALLY AVOID: Coadministration of margetuximab and anthracyclines may increase the risk of cardiac dysfunction. Margetuximab and anthracyclines are individually cardiotoxic and may have additive effects during coadministration. Four months after discontinuation, margetuximab concentrations decreased to approximately 3% of its steady-state trough serum concentration. Therefore, use of anthracyclines within 4 months after stopping margetuximab may also carry a higher risk of cardiac dysfunction.

MANAGEMENT: Anthracycline-based therapy should be avoided during and for up to 4 months after stopping use of margetuximab. If anthracyclines must be used sooner, the patient's cardiac function should be closely monitored.